Objectives: To determine opioid-prescribing practices to the orthopaedic trauma (OT) population at one Level I trauma center.
INTRODUCTION
Opioid-based narcotics are commonly prescribed for pain control in orthopaedic surgery patients and have a high risk for abuse and dependence. 1, 2 In 2001, Joint Commission (JCHAO) introduced mandatory pain assessment standards in all patients and cited that "pain is the fifth vital sign" as an example of a strategy for some clinical settings. 3 Concurrently, there was a massive marketing campaign by pharmaceutical companies promoting prescription opioids. This has resulted in the United States developing a largely pharmaceutical approach to pain management. The result is that the United States consumes most of the world's prescription opioids while representing less than 5% of the world's population. 4 Concurrently, unintentional overdose deaths have risen sharply, largely because of an increase in overdoses involving prescription opioids often obtained from a secondary nonmedical source. 5, 6 Prescription opioid use now results in more deaths than cocaine and heroin combined each year. 7 Of the medical specialties in the United States, orthopaedic surgeons are the third highest prescribers of opioids. 8 Studies have evaluated the prescribing habits of orthopaedic surgeons and the effect of opioids postoperatively during various procedures. 9, 10 Patients with hip and ankle fractures treated in the Netherlands who did not receive postoperative opioids have been shown to have less postoperative pain and more satisfaction than patients with the same injuries in the United States who received opioids. 9, 11 During this same period, basic science studies have negatively influenced US Orthopaedic Surgeons attitudes about nonsteroidal anti-inflammatory drugs in the setting of healing fractures, despite a lack of good clinical contraindication data and widespread use internationally. 9, [11] [12] [13] This ushered in an era of opioid monotherapy for orthopaedic injuries. On the contrary, opioids are associated with worse clinical outcomes in patients with occupational musculoskeletal disorders and patients undergoing total knee arthroplasty, reverse shoulder arthroplasty, and spine surgery. 1, 10, 14, 15 Physicians and nonphysician providers who manage patients with orthopaedic trauma (OT) should be particularly well versed in risk assessment and mitigation strategies because many in this population are at greater risk. [16] [17] [18] [19] [20] Massey et al evaluated patients with a positive toxicology screen at the time of injury and found these patients to be at an increased risk for prolonged opioid use compared with those whose toxicology screen was negative. 17 In evaluating additional preinjury risk factors, Helmerhorst et al found patients with anxiety before their surgery had greater pain scores and postinjury disability compared with those without anxiety. 20 The study also found patients who continued to use opioids 1-2 months after their date of surgery had more disability and psychological distress than those who were no longer taking opioids. 20 Patients with preinjury opioid use are more likely to have multiple opioid prescribers postoperatively and continue opioids for a longer duration after surgery. 17, 18 Substance abuse is another important risk factor for subsequent abuse of prescription opioids. 13 Moreover, rates of iatrogenically induced addiction show wide variation and predictability in the literature [21] [22] [23] [24] [25] [26] [27] and increase with duration of exposure. [28] [29] [30] [31] Over the course of the past 20 years, extended release/ long-acting opioids such as Oxycontin gained widespread use based on retracted claims of improved safety, 32 and unsubstantiated claims of improved efficacy versus short acting opioids. [33] [34] [35] [36] [37] [38] "Tamper resistant" extended-release opioids were developed to curb abuse and misuse. 32, 39 It has now been demonstrated that these drugs can still be abused and remain highly addictive. 40, 41 Subsequent studies have not proven that extended-release narcotics have greater efficacy than immediate release. [33] [34] [35] [36] [37] [38] Despite these data and the Food and Drug Administration black label warning 42 in 2001 (updated in 2015), extended-release and long-acting (ER/LA) opioids are still commonly prescribed. Another system implemented to identify patients at risk for opioid abuse and misuse is prescription drug monitoring programs. 43 Despite these efforts, the opioid epidemic continues to escalate, and a more comprehensive and efficient method to stratify and identify patients at risk for nontherapeutic opioid use is needed. 44 The purpose of this study is to determine the opioid-prescribing practices in the OT population at a single institution.
PATIENTS AND METHODS

Setting and Patients
A retrospective study of prescribing patterns at the time of inpatient discharge in adult patients with OT (including operative and nonoperative cases) admitted to a Level 1 trauma center over a 1-month period was conducted. Patients were discharged by either the OT team or the Trauma Critical Care team. This audit was limited to 1 month, because it was conducted as a basis for a series of multidisciplinary process improvements planned across the health system gradually over the next several months to years. All OT discharges were conducted at the single Level 1 trauma center. The expansive health system (15 hospitals, 6 freestanding Emergency Departments (EDs), 30 Urgent Cares, and 350 clinics) on a common electronic medical record system was used to capture follow-up data on discharged patients. This is possible because the health care system maintains the dominant and growing footprint in a highly consolidated health care market. More importantly, the system scores highly in markers of patient loyalty such as patient satisfaction and employee satisfaction. [45] [46] [47] Within system follow-up, rates are quite high in both data analytic reviews and retrospective studies. [48] [49] [50] [51] 
Data Collection and Measures
Discharge prescription details to include prescriber, drug, dose, and duration were recorded. The same details were recorded for subsequent outpatient prescriptions up to 2 months after discharge. 20, 52 In addition, demographic information, including sex, age, and employment status, were abstracted from the electronic medical record into REDCap (Vanderbilt University, Nashville, TN). 53 Relevant medical information abstracted included mechanism of injury, injury severity score (ISS), length of stay, and toxicology results. Daily morphine milligram equivalent (MME) dose was calculated for each prescription. 54 We established a panel of subject matter experts from a diverse background of health care and public health to conduct an evidence-based review to identify objective risk factors for abuse, misuse, and diversion. 39 This panel included members from Public Health, Orthopaedic Trauma, Addiction Medicine, Poison Control, Pain Management, Emergency Medicine, Internal Medicine, Trauma/Critical Care, and Information Technology. 55 Risk factors were further limited to those that were objectively searchable in the electronic medical record. Included risk factors were (1) current opioid prescription with .50% remaining expected ("early refills"); (2) 2+ visits to the ED or Urgent Care with onsite treatment with opioids within the 30 days before the prescription; (3) 3+ prescriptions for opioids within the 30 days before the prescription; (4) any previous presentation for opioid overdose within the EMR; and (5) any positive screen for blood alcohol content (BAC), cocaine, or marijuana within the EMR. [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] We conducted focus group style interviews with prescribers to determine appropriateness of the thresholds of the risk factors. All urgent care and ED visits, as well as preinjury and post prescription information, were abstracted retrospectively from the EMR. Missing data were less of a concern, since limited our variables to orders/ prescriptions, diagnostic codes, and lab results that are consistently and reliably documented within the EMR. Based on these risk factors, if a patient had one or more, they were classified as "at risk."
Data Analysis
Descriptive statistics were used to characterize the patient population and rates of opioid-prescribing. T tests were performed to determine whether a difference in mean values existed for MME, duration of prescriptions, and number of prescriptions between patients receiving extended release versus immediate release; as well as between "at risk" patients and patients without risk factors. Z tests were used to detect a difference in proportion of "at risk" patients between those prescribed extended release versus immediate release opioids. A significance level of 0.05 was used. Statistical analysis was performed using SAS.
RESULTS
One hundred thirty-five discharge prescriptons were written for 110 patients with orthopaedic injuries during the review period (Table 1 ). All patients received opioids at the time of discharge ( Table 2 ). The MMEs prescribed at the time of discharge was 114 mg (54-300 mg) for a mean of 7.21 days (2-36.7 days). There was no difference in the mean MMEs prescribed at discharge between patients who underwent surgery and those who did not (117 mg vs. 113 mg, P = 0.70).
The most prevalent age group was 30-49 (28.2%) years. The most common mechanism of injury was a motor vehicle collision (32.7%). The mean ISS was 11.2. Fifty-three percent of patients had at least 1 operative injury. ISS was not significantly different between patients treated operatively versus nonoperatively. Fifty percent of the patients were unemployed at their time of injury, which is a risk factor for opioid overdose. 63 The mean hospital length of stay was 5.4 days (range 1-25 days).
At the time of admission, 33.6% received a toxicology screen. 16.4% of all presenting patients (almost half of those who were tested) had a positive BAC or toxicology screen for cocaine or marijuana (Table 3) .
Patients who were prescribed extended-release oxycodone had a mean of 1.74 opioid prescriptions provided to them at the time of discharge, compared with 1.09 for those who did not (P = 0.53). Patients who were prescribed extended-release oxycodone at the time of discharge were prescribed significantly more MMEs than those who did not (149 mg vs. 107 mg, P , 0.05). There was no difference in the ISS of patients who received extended-release oxycodone and those who did not (12.3 vs. 12.4, P = 0.971). These ER/LA prescriptions were for a significantly longer duration after discharge (16.3 days vs. 5.18 days, P , 0.05).
Twenty-five percent of the patients with OT met some criteria that indicate risk for misuse, abuse, or diversion of prescription opioids on admission for the baseline injury (Table 4) . While patients with preinjury risk factors were prescribed discharge opioids for a similar duration (7.00 days vs. 7.30 days, P = 0.81) than those without risk factors, they were prescribed significantly more MMEs than those without (130 vs. 108, P , 0.05), and were more likely to receive ER/LA opioids than those without (42.11% vs. 21.98%).
During the 2 months of follow-up, 42.7% received at least 1 additional prescription for narcotics. The most commonly prescribed opioids during follow-up visits were hydrocodoneacetaminophen (36.4%), followed by oxycodoneacetaminophen (12.7%) and other opioids (2.7%). There was a mean of 0.37 visits per patient (range 0-4 visits) in which an opioid prescription was provided during the followup period. Patients were provided an average of 1.1 opioid 
DISCUSSION
Until very recently, there has been very little education to prescribers on pain management strategies [66] [67] [68] and risk other than the opioid monotherapy that has dominated the past 2 decades. Wide variance in prescribing practices to include the use of long-acting opioids has been anecdotally noted in the trauma population, but publications in this area are lacking. Despite growing evidence of the link between prescription opioids and worse functional outcome, addiction, and even death, there has been a lack of translation of these data to clinical practice. Unfortunately, there has been limited education in the trauma community in the areas of risk mitigation, and nonpharmaceutical strategies for pain management.
Prescribers who are discharging patients with OT need to be aware that this is an at-risk population. 17, 18 Risk Evaluation and Mitigation Strategies should be used in these patients. 69, 70 More than 25% of the patients in this study had risk factors for abuse, misuse, or diversion of prescription opioids at the time of injury and were prescribed alarmingly high MMEs at the time of discharge. Patients who were prescribed extended-release oxycodone at the time of discharge received significantly more MMEs.
In this study, almost 8% of this patient population had an existing/active opioid prescription with greater than 50% of the prescription remaining at the time of injury. Four percent of the patients had received 3 or more opioid prescriptions within the 30 days before admission and 2% of the patients had 2 or more onsite emergency department or urgent care visits resulting in administration of opioids. Patients in this study with preinjury risk factors received significantly more MMEs at the time of discharge, and during their follow-up visits than patients who did not. This is not only of concern because these are patients who will be at high risk of continued nontherapeutic opioid use after injury, but preinjury opioid use has been associated with poor outcomes across multiple orthopaedic subspecialties. 1, 14, 15 In evaluating patients with OT at the time of admission, Massey et al 17 found 72% of the patients to have either a positive BAC or toxicology screen. This is of importance for multiple reasons. Patients with a positive toxicology screen on admission have been found to be at an increased risk for prolonged opioid use. 17 Nineteen percent of the patients in this study had either a positive BAC or toxicology screen for cocaine or marijuana on admission. This group of patients is at high risk for misuse or abuse of prescription opioids, and strategies to mitigate this risk should be undertaken by prescribers throughout the inpatient stay and at the time of discharge. Clinical decision support built within the electronic medical record to identify risk for abuse or misuse would be a beneficial step to engaging in primary prevention by using multimodal strategies and cognitive behavioral therapy to appropriately reduce dose and duration of opioid prescriptions. 71, 72 Furthermore, recognition that certain mental illnesses are risk factors for nontherapeutic opioid use 73 can help physicians direct more holistic treatment for these patients. Twenty-two percent of patients in this study had been diagnosed with anxiety at some point, and 21 percent of patients had been diagnosed with depression.
In this study of patients with OT who received a prescription opioid at the time of discharge, oxycodoneacetaminophen was the most commonly prescribed opioid. Almost one fifth of the patients in this study received a prescription for extended-release oxycodone at the time of discharge. Most of these patients received an immediate release opioid as well. Patients discharged with extendedrelease oxycodone averaged 149 MMEs and received 141 MMEs per day during their follow-up visits. These are both well above risk thresholds for overdose 5, 74 and the maximum of 90 MMEs per day the Centers for Disease Control and Prevention recommends for treating chronic pain. 75 Despite the attempt to reduce the danger of OxyContin with abusedeterrent formulations, it is now clear that this remains a highly addictive drug with abuse potential and potentially devastating adverse effects. 40, 41 The manufacturer of OxyContin has paid over $600 million in fines for inappropriately marketing the drug as nonaddictive and having less potential for abuse. 32 Most of the literature citing the benefit and decreased abuse potential of extended-release OxyContin was funded by the manufacturer of the drug. [76] [77] [78] [79] There has been a slight slowing of the increase in opioid-related deaths in some states that is thought to be a result of stricter policies and regulations rather than the reformulation of OxyContin. [80] [81] [82] [83] The Academy of Orthopaedic Surgeons (AAOS) issued an information statement recommending against the use of extended-release opioids for the treatment of acute pain. 84 In this study, all the extended-release opioid prescriptions were written by nonorthopaedic prescribers. This study highlights that despite the risks associated with extended-release opioids, they are still being prescribed at alarming rates in an at-risk population in an opioid monotherapy regimen. In addition to opioid prescriptions at the time of discharge, 43% of patients received an additional opioid prescription during the follow-up period. Care must be taken when prescribing opioids during follow-up visits, as opioid use 1-2 months past the date of surgery is associated with increased disability and psychological distress. 20 Data suggest that 50% of patients taking prescription opioids for 3 months will continue to take them at 5 years. 28 During the 2-month follow-up period of this study, an additional 9% of patients developed new risk criteria.
Unfortunately, there are no current clinical practice guidelines on pain management in orthopaedic surgery to include OT. 85 Some guidelines do exist, like the CDC guidelines for chronic pain 75 and guidelines from other specialties and organizations. 86 Acute postinjury or postsurgery guidelines for pain management are scarce and demonstrate significant research gaps. 87, 88 There are several limitations of this study.
(1) It is retrospective in nature and limited to prescriptions provided within our health care system. The primary focus of the study is discharge prescriptions which makes it generalizable to any busy Level 1 trauma center. Because of the large size of the health system in such a consolidated market, the follow-up data on prescriptions has some validity. (2) The sample size is small and limited to patients admitted over a 30-day period and followed for 2 months after injury. This audit of prescribing practices was limited to 1 month to define the problem and target gaps for improvement. Subsequent to the audit, our health system began a series of interventions as an iterative improvement process that is still ongoing toward safer prescribing and appropriate, comprehensive pain management. (3) Patients who were previously prescribed opioids for cancer pain were not excluded. This is a patient population that is known to be prescribed higher MMEs per day than the general population. The number of cancer patients however should be quite small.
Management of pain after OT is complex and requires surgeons to be attuned to need to balance patient safety with the need to adequately and appropriately manage pain. Our results show that 25% of patients with OT have risk factors for abuse, misuse, or diversion of prescription opioids at baseline injury. An additional 9% of patients with OT became at-risk in the follow-up period. These data suggest that a move away from opioid monotherapy into a more comprehensive pain management strategy to include multimodal pain management, cryotherapy, cognitive behavioral therapy 71, 72 and others is needed. Orthopaedic practices and hospitals should develop standardized opioid-prescribing protocols and encourage continuing medical education on opioid safety and appropriate use for physicians and nonphysician providers who prescribe opioids. 89 To our knowledge, this study is the first to quantitatively evaluate the discharge prescribing practices in an at-risk OT population. These data are essential as the first step in process improvement for safer opioid prescribing. Improvements should include the use of Risk Evaluation and Mitigation Strategies, development, and utilization of prescribing guidelines, and understanding of nonpharmaceutical strategies for pain management. Furthermore, these data should compel clinicians to consider using MME calculators and checking the state Prescription Drug Monitoring Database when prescribing opioids and to eliminate the use of ER/LA opioids for acute injury/pain. It also warrants a re-evaluation of the risk of nonsteroidal anti-inflammatory drugs versus opioids in the setting of musculoskeletal injury.
CONCLUSIONS
Pain management after OT continues to be opioid-centric despite involving a population at risk. Further focus on prescriber and patient education, risk evaluation with mitigation, guideline development, and comprehensive pain management strategies are warranted in the OT population.
